Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.5% | 21.5% | -33.1% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 97.9% | 5.5% | -0.8% | 38.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -125.5% | -169.9% | -216.8% | -101.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -135.3% | -186.2% | -235.5% | -106.6% |
| EPS Diluted | -0.25 | -0.33 | -0.36 | -0.26 |
| % Growth | 24.2% | 8.3% | -38.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |